OBJECTIVES: To describe lipid management over time in a cohort of insured patients with diabetes and evaluate differences between African American and white patients. STUDY DESIGN: Automated claims data were used to identify a cohort of 11,411 patients with diabetes in 1997 to 1998. Patients were followed through 2007. METHODS: Rates of hypercholesterolemia testing, treatment, and goal attainment were measured annually. Treatment was determined by a claim for lipid-lowering agents, and goal attainment was defined as a low-density lipoprotein cholesterol (LDL-C) level <100 mg/dL. RESULTS: During the study period, LDL-C testing increased from 48% to 70% among African American patients and from 61% to 77% among white patients. Treatment with lipid-lowering drugs increased from 23% to 56% among African American patients and 33% to 61% among white patients. The proportion at goal increased from 35% to 76% and from 24% to 59% among white and African American patients, respectively. African American patients were less likely to be tested for LDL-C (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.73-0.86), treated with lipidlowering agents (OR 0.72; 95% CI 0.65-0.80), have their medication dosage altered (OR 0.65; 95% CI 0.59-0.73), or attain LDL-C goal (OR 0.59; 95% CI 0.56-0.63) compared with white patients. CONCLUSIONS: Although rates of LDL-C testing, treatment, and goal attainment improved over time, racial disparities in dyslipidemia management continued to exist. Further studies to determine the causes of differences in management by race are warranted.
OBJECTIVES: To describe lipid management over time in a cohort of insured patients with diabetes and evaluate differences between African American and white patients. STUDY DESIGN: Automated claims data were used to identify a cohort of 11,411 patients with diabetes in 1997 to 1998. Patients were followed through 2007. METHODS: Rates of hypercholesterolemia testing, treatment, and goal attainment were measured annually. Treatment was determined by a claim for lipid-lowering agents, and goal attainment was defined as a low-density lipoprotein cholesterol (LDL-C) level <100 mg/dL. RESULTS: During the study period, LDL-C testing increased from 48% to 70% among African American patients and from 61% to 77% among white patients. Treatment with lipid-lowering drugs increased from 23% to 56% among African American patients and 33% to 61% among white patients. The proportion at goal increased from 35% to 76% and from 24% to 59% among white and African American patients, respectively. African American patients were less likely to be tested for LDL-C (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.73-0.86), treated with lipidlowering agents (OR 0.72; 95% CI 0.65-0.80), have their medication dosage altered (OR 0.65; 95% CI 0.59-0.73), or attain LDL-C goal (OR 0.59; 95% CI 0.56-0.63) compared with white patients. CONCLUSIONS: Although rates of LDL-C testing, treatment, and goal attainment improved over time, racial disparities in dyslipidemia management continued to exist. Further studies to determine the causes of differences in management by race are warranted.
Authors: Richard Grant; Alyce S Adams; Connie Mah Trinacty; Fang Zhang; Ken Kleinman; Stephen B Soumerai; James B Meigs; Dennis Ross-Degnan Journal: Diabetes Care Date: 2007-01-26 Impact factor: 19.112
Authors: J B Echouffo-Tcheugui; L A Sargeant; A T Prevost; K M Williams; R S Barling; R Butler; T Fanshawe; A L Kinmonth; N J Wareham; S J Griffin Journal: Diabet Med Date: 2008-12 Impact factor: 4.359
Authors: L Keoki Williams; Christine L Joseph; Edward L Peterson; Karen Wells; Mingqun Wang; Vimal K Chowdhry; Matthew Walsh; Janis Campbell; Cynthia S Rand; Andrea J Apter; David E Lanfear; Kaan Tunceli; Manel Pladevall Journal: J Allergy Clin Immunol Date: 2007-10-22 Impact factor: 10.793
Authors: Jennifer Elston Lafata; Andrew J Karter; Patrick J O'Connor; Heather Morris; Julie A Schmittdiel; Scott Ratliff; Katherine M Newton; Marsha A Raebel; Ram D Pathak; Abraham Thomas; Melissa G Butler; Kristi Reynolds; Beth Waitzfelder; John F Steiner Journal: J Gen Intern Med Date: 2016-02 Impact factor: 5.128
Authors: Amrita Mukhopadhyay; Harmony R Reynolds; Arielle R Nagler; Lawrence M Phillips; Leora I Horwitz; Stuart D Katz; Saul Blecker Journal: BMC Cardiovasc Disord Date: 2022-08-04 Impact factor: 2.174
Authors: Deborah A Taira; Brendan K Seto; James W Davis; Todd B Seto; Doug Landsittel; Wesley K Sumida Journal: J Pharm Health Serv Res Date: 2017-08-07